LLY

759.22

+1.45%↑

JNJ

177.16

+0.11%↑

ABBV

217.73

-0.06%↓

UNH

341.3

-1.41%↓

AZN

77.54

-0.28%↓

LLY

759.22

+1.45%↑

JNJ

177.16

+0.11%↑

ABBV

217.73

-0.06%↓

UNH

341.3

-1.41%↓

AZN

77.54

-0.28%↓

LLY

759.22

+1.45%↑

JNJ

177.16

+0.11%↑

ABBV

217.73

-0.06%↓

UNH

341.3

-1.41%↓

AZN

77.54

-0.28%↓

LLY

759.22

+1.45%↑

JNJ

177.16

+0.11%↑

ABBV

217.73

-0.06%↓

UNH

341.3

-1.41%↓

AZN

77.54

-0.28%↓

LLY

759.22

+1.45%↑

JNJ

177.16

+0.11%↑

ABBV

217.73

-0.06%↓

UNH

341.3

-1.41%↓

AZN

77.54

-0.28%↓

Search

MannKind Corp

Abrir

SetorSaúde

5.41 1.69

Visão Geral

Variação de preço das ações

24h

Atual

Mín

5.27

Máximo

5.44

Indicadores-chave

By Trading Economics

Rendimento

-12M

668K

Vendas

-1.8M

77M

P/E

Médio do Setor

48.909

35.664

Margem de lucro

0.873

Funcionários

403

EBITDA

-17M

9.7M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+91.26% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de nov. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

518M

1.7B

Abertura anterior

3.72

Fecho anterior

5.41

Sentimento de Notícias

By Acuity

50%

50%

185 / 371 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bullish Evidence

MannKind Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

16 de set. de 2025, 17:03 UTC

Grandes Movimentos do Mercado

BrainsWay Shares Rise on FDA Clearance of Major Depressive Disorder Treatment

16 de set. de 2025, 16:49 UTC

Grandes Movimentos do Mercado
Aquisições, Fusões, Aquisições de Empresas

GD Culture Shares Drop After Deal for Pallas Capital

16 de set. de 2025, 16:11 UTC

Grandes Movimentos do Mercado

Corbus Shares Rise on FDA Fast-Track Designation for Cancer Drug

16 de set. de 2025, 23:40 UTC

Conversa de Mercado

Nikkei May Decline as Yen Strengthens -- Market Talk

16 de set. de 2025, 23:34 UTC

Conversa de Mercado

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

16 de set. de 2025, 23:20 UTC

Conversa de Mercado

Restaurant Brands NZ Can Outperform When Cycle Turns -- Market Talk

16 de set. de 2025, 21:10 UTC

Aquisições, Fusões, Aquisições de Empresas

U.S. Investors, Trump Close In on TikTok Deal With China -- WSJ

16 de set. de 2025, 20:51 UTC

Conversa de Mercado

U.S. Home Sales, New Home Listings Fall in August -- Market Talk

16 de set. de 2025, 20:50 UTC

Conversa de Mercado

Energy & Utilities Roundup: Market Talk

16 de set. de 2025, 20:50 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Basic Materials Roundup: Market Talk

16 de set. de 2025, 20:25 UTC

Ganhos

The AI Trade Has Stocks Near Highs Again. Some Tech Names Remain on the Sidelines -- Barrons.com

16 de set. de 2025, 20:24 UTC

Ganhos

These Stocks Moved the Most Today: Oracle, Tesla, Alphabet, Dave & Buster's, Chipotle, and More -- Barrons.com

16 de set. de 2025, 19:19 UTC

Conversa de Mercado

U.S. Natural Gas Futures Extend Winning Streak -- Market Talk

16 de set. de 2025, 18:52 UTC

Conversa de Mercado

Oil Futures Advance on Russia Concerns, Weak Dollar -- Market Talk

16 de set. de 2025, 18:44 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

16 de set. de 2025, 18:44 UTC

Conversa de Mercado

EssilorLuxottica Well-Positioned in Growing Smart-Glasses Market -- Market Talk

16 de set. de 2025, 18:40 UTC

Aquisições, Fusões, Aquisições de Empresas

Details Emerge on U.S.-China TikTok Deal -- WSJ

16 de set. de 2025, 18:38 UTC

Conversa de Mercado

Meta Seen With Long-Term Opportunity to Lead in Smart Glasses -- Market Talk

16 de set. de 2025, 18:19 UTC

Conversa de Mercado

Gold Settles at New High Ahead of Fed Decision -- Market Talk

16 de set. de 2025, 18:01 UTC

Conversa de Mercado

U.S. Dollar Weakness Supports Oil's Gains -- Market Talk

16 de set. de 2025, 17:34 UTC

Conversa de Mercado

Any Question the Bank of Canada Will Cut Now Look to Have Vanished -- Market Talk

16 de set. de 2025, 16:53 UTC

Ganhos

Software Companies Are Fighting Back With AI. The Stocks Are Still Hurting. -- Barrons.com

16 de set. de 2025, 16:20 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Basic Materials Roundup: Market Talk

16 de set. de 2025, 16:15 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Global Commodities Roundup: Market Talk

16 de set. de 2025, 16:09 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Global Energy Roundup: Market Talk

16 de set. de 2025, 16:09 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Canada Industry Minister to Meet Mining CEOs on Merger -- Market Talk

16 de set. de 2025, 15:35 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

16 de set. de 2025, 15:35 UTC

Conversa de Mercado

Gold Soars Past $3,700 Ahead of Fed Decision -- Market Talk

16 de set. de 2025, 15:22 UTC

Conversa de Mercado

More Investors Think Dollar is Overvalued in Latest BofA Survey -- Market Talk

16 de set. de 2025, 15:21 UTC

Conversa de Mercado

Sterling Considered Most Overvalued in Nearly 10 Years -- Market Talk

Comparação entre Pares

Variação de preço

MannKind Corp Previsão

Preço-alvo

By TipRanks

91.26% parte superior

Previsão para 12 meses

Média 10.29 USD  91.26%

Máximo 15 USD

Mínimo 7 USD

Com base em 7 analistas de Wall Street que oferecem metas de preço de 12 meses para MannKind Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

7 ratings

7

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

4.079 / 4.323Suporte e Resistência

Curto Prazo

Bullish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Weak Bearish Evidence

Sentimento

By Acuity

185 / 371 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
help-icon Live chat